D
BioMarin Pharmaceutical Inc. BMRN
$58.14 $0.290.50% NASDAQ
Recommendation
Prev Close
$57.85
Volume
3,817,498
Avg Vol (90D)
2,013,040
Market Cap
$11.09B
Dividend & Yield
--
52-Week Range
$52.93 - $94.85
P/E (TTM)
21.47
EPS (TTM)
$2.70
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Assetmark Inc. Boosts Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
8/2/2025 - Ticker Report
Banque Cantonale Vaudoise Acquires Shares of 16,000 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
8/2/2025 - MarketBeat
GSA Capital Partners LLP Has $1.05 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
8/2/2025 - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Pacer Advisors Inc.
8/2/2025 - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
8/2/2025 - MarketBeat
What's Next: Biomarin Pharmaceutical's Earnings Preview
8/1/2025 - Benzinga
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
8/1/2025 - PR Newswire
Banque Cantonale Vaudoise Takes $1.13 Million Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
8/1/2025 - Ticker Report
Wealthquest Corp Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
8/1/2025 - Ticker Report
Bayforest Capital Ltd Makes New Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
8/1/2025 - MarketBeat
BioMarin Pharmaceutical (BMRN, $57.85) Moving Average Convergence Divergence (MACD) Histogram turned negative on July 31, 2025
8/1/2025 - Tickeron - Stocks
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Tredje AP fonden
7/30/2025 - MarketBeat
Allianz Asset Management GmbH Raises Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
7/30/2025 - MarketBeat
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
7/29/2025 - Zacks Investment Research
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
7/28/2025 - Zacks Investment Research
BioMarin Pharmaceutical (BMRN) to Release Earnings on Monday
7/28/2025 - MarketBeat
10 Most Profitable Biotech Stocks to Invest in Now
7/25/2025 - Insider Monkey
1 Mid-Cap Stock Worth Investigating and 2 We Turn Down
7/25/2025 - StockStory Articles
Will Escalating Medical Costs Dampen Centene's Q2 Earnings?
7/23/2025 - Zacks Investment Research
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $96.00 at Morgan Stanley
7/23/2025 - Ticker Report
Morgan Stanley Issues Pessimistic Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price
7/22/2025 - MarketBeat
BioMarin Pharmaceutical Inc (BMRN) Announces Upcoming Q2 2025 Financial Results Conference Call ...
7/22/2025 - GuruFocus
BMRN: Morgan Stanley Adjusts Price Target for BioMarin Pharmaceutical BMRN Stock News
7/22/2025 - GuruFocus
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
7/22/2025 - PR Newswire
Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
7/22/2025 - Simply Wall St
Income Statement
Total Revenue (TTM)
$2.95B
EBITDA (TTM)
$845.65M
EBIT (TTM)
$754.50M
Net Income (TTM)
$523.88M
Balance Sheet
Total Assets (Q)
$7.15B
Total Debt (Q)
$601.96M
Total Liabilities (Q)
$1.35B
Book Value Per Share (Q)
$30.21
Cash Flow
Cash from Operations (TTM)
$700.26M
Cash from Investing (TTM)
$122.49M
Cash from Financing (TTM)
-$522.43M
Net Change in Cash (TTM)
$301.81M
Filings
Filing Date
Friday, May 2, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
0.56
7-Day Total Return
-2.56%
30-Day Total Return
5.25%
60-Day Total Return
-2.52%
90-Day Total Return
-19.24%
Year to Date Total Return
-12.56%
1-Year Total Return
-31.29%
2-Year Total Return
-34.67%
3-Year Total Return
-31.93%
5-Year Total Return
-52.36%
52-week Low
Apr 09, 2025 - $52.93
52-week High
Aug 20, 2024 - $94.85
Valuation
Market Cap
$11.09B - Large Cap
Enterprise Value
$10.42B
Price/Sales (TTM)
3.85
Price/Book (Q)
1.91
Dividends and Shares
Shares Outstanding
196.47
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.biomarin.com
Phone Number
415 506 6700
Address
770 Lindaro Street
San Rafael, CA 94901
Country
United States
Year Founded
1996
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United... more
NASDAQ 08/01/2025 4:00PM Eastern Quotes delayed